Table 2.1. Prospective studies of HBV surface antigen (HBsAg)-seropositive people for the development of hepatocellular carcinoma (HCC)

Region, reference, location	Subjects (age)	HBsAg seroprevalence	Mean duration of follow-up (years)	No. of cases of HCC	Annual incidence (cases/-100000)	RR (95% CI)
Africa						
Evans *et al.* (1998) Senegal	Men in Senegalese Army	2611 HBsAg+ 10 425 HBsAg-	Approx 4	14	68.3 (among HBsAg+)	NR
Americas						
Nomura *et al.* (1996) Hawaii, USA	Men of Japanese ancestry (born 1900–1919) Controls	7498 HBsAg+ 24 HCCs (15 HBsAg+, 0 HCV+) 72 controls (2HBsAg+, 1HCV+)	NR (approx 24)	28 (but only 24 had available sera)	NR	43.0 (5.7–325.5)
Asia						
Chang *et al.* (1994) Taiwan, China	Men (30–85 years)	NR HBsAg + 38 HCC (24 HBsAg +) 152 controls (10 HBsAg +)	NR (approx 6)	24 HBsAg+ 14 HBsAg-	NR	26.48 (7.92–88.56) Excluding HCV+ 44.57 (10.17–195.30) Nested case–control analysis. See Chen et al. (1993) for additional description of the cohort.
Lu *et al.* (1998) Qidong, China	Men (20–60 years)	737 HBsAg+ 699 HBsAg-	NR (approx 10)	47 3	824 71	11.61
Yang *et al.* (2002) Taiwan, China	Men (30–65 years)	2361 HBsAg+ (1991 HBsAg+/HBeAg-) (370 HBeAg+/ HBeAg+) 9532 HBsAg-/HBeAg-	7.77	82 50 32 29	[451] 324 1169 39	[11.51 (7.54–17.57)] 9.6 (6.0–15.2) 60.2 (35.5–102.1) 1.0 For more information on the study cohort, see Wang et al. (1996).

DRAFT

Table 2.1. Prospective studies of HBV surface antigen (HBsAg)-seropositive people for the development of hepatocellular carcinoma (HCC)

Region, reference, location	Subjects (age)	HBsAg seroprevalence	Mean duration of follow-up (years)	No. of cases of HCC	Annual incidence (cases/-100000)	RR (95% CI)
Evans *et al.* (2002) Haimen City, China	Men and women (25–64 years)	Men 8795 HBsAg+ 49 659 HBsAg- Women 2711 HBsAg+ 22 629 HBsAg-	7.43 7.16	 643 257 61 16	 1030 69 320.2 9.9	 18.8 (16.0–22.1) Adjusted for other factors 33.2 (17.0–65.0) Adjusted for other factors For additional results from the cohot, see London et al. (1995), Tang et al. (2004), Chen et al. (2005a).
Wang *et al.* (2003) Taiwan, China	Men (30–65 years)	2416 HBsAg+ 9421 HBsAg-	7.8	86 29	NR NR	13.1 (8.6–20.1)
Tanaka *et al.* (2004) Osaka, Japan	Blood donors (men and women 40–64 years)	2519 HBsAg+/ HCV- 1927 HCV+/ HBsAg- 25 HCV+ /HBsAg+ 150 379 HCV-/ HBsAg-	8.25	45 52 3 27	203 334 1677 2	74 (45–121) 36 (21–62) 161 (46–557) 1.0 Adjusted for sex, age, ALT level and cholesterol level.
Gwack *et al.* (2007) Korea	Men and women 30 +	HBsAg+ 296 HBsAg- 6582	950 24017	10 26	1052.6 108.3	[9.6 (4.7-19.9)]

DRAFT

Table 2.1. Prospective studies of HBV surface antigen (HBsAg)-seropositive people for the development of hepatocellular carcinoma (HCC)

Region, reference, location	Subjects (age)	HBsAg seroprevalence	Mean duration of follow-up (years)	No. of cases of HCC	Annual incidence (cases/-100000)	RR (95% CI)
Australia						
Amin *et al.* (2006)	People notified as HBV or HCV positive to NSW State Health Department	All				
		39 109 HBsAg	5.2	124	0.65	30.6 (25.7–36.5)
		75 834 HCV	4.6	143	0.40	22.5 (19.1–26.5)
		2604 HBV/HCV	3.8	6	0.59	30.3 (13.6–67.5
		Men	NR			
		20 808 HBsAg		105	1.04	30.6 (25.3–37.1)
		47 903 HCV		101	0.46	18.7 (15.4–22.7)
		1932 HBV/HCV		5	0.65	27.5 (11.4–65.9)
		Women	NR			
		18 301 HBsAg		19	0.21	30.7 (19.6–48.1)
		27 931 HCV		42	0.31	44.0 (32.6–59.6)
		672 HBV/HCV		1	0.39	64.2 (9.0–455.8)
Europe						
Crook *et al.* (2003) England and Wales	Blood donors	2681 HBsAg+ men	22	20	33.5	26 (16.0–40.5)
		977 HBsAg+ women		1	4.4	10 (NR)
		National population rates as comparator				
Ribes *et al.* (2006) Spain	Blood donors	1656 HBsAg+ men	20.5	14	34.1	14.1 (7.7-23.6)
		631 HBsAg+ women		1	NR	1.5 (0.02-8.29)
		8783 HBsAg-men		NR	NR	
		6721 HBsAg-women		NR	NR	

RR, Relative Risk or Rate Ratio or Risk Ratio; NR, not reported

DRAFT